اختيار الموقع            تسجيل دخول
 

تصفح المحتوي RDA
التصفح حسب الموضوعات
التصفح حسب اللغة
التصفح حسب الناشر
التصفح حسب تاريخ النشر
التصفح حسب مكان النشر
التصفح حسب المؤلفين
تصفح الهيئات
التصفح المؤتمرات
التصفح حسب نوع المادة
التصفح حسب العلاقة بالعمل
تم العثور علي : 11
 تم العثور علي : 11
  
 
إعادة البحث

Thesis 2016.
Hassan, Hanan Mohammed .
618 أمراض النساء والولادة والموضوعات ذات الصلة  
N-Terminal Pro Brain
تصفح الوعاء  

Thesis 2022
Megahed, Dina Mahmoud Fouad .
616 الأمراض  
تصفح الوعاء  

Thesis 2017
Abdel Meguid,Iman Mostafa
617 الجراحة والموضوعات ذات الصلة  
AD-MSCs: Adipose Derived Mesenchymal Stem Cells
ALCAM: Activated Leukocyte Cell Adhesion Molecule
ASCs: Adult Stem Cells
Bcl-2: B-cell lymphoma 2
bFGF: basic Fibroblast Grwoth Factor
BIR: Baculovirus IAP Repeat
BIRC1/NAIP: Baculoviral IAP Repeat Containing 1/NLR family Apoptosis Inhibitory Protein
BIRC2/cIAP1: Baculoviral IAP Repeat Containing 2/ cellular Inhibitor of Apoptosis Protein 1
BIRC3/cIAP2: Baculoviral IAP Repeat Containing 3/ cellular Inhibitor of Apoptosis Protein 2
BIRC4/XIAP: Baculoviral IAP Repeat Containing 4/X-linked Inhibitor of Apoptosis
BIRC5: Baculovirus IAP RepeatContaining 5
BIRC6:Baculovirus IAP RepeatContaining 6
BIRC7:Baculovirus IAP RepeatContaining 7
BIRC8: Baculovirus IAP RepeatContaining 8
BM: Bone Marrow
BM-MSCs: Bone Marrow Mesenchymal Stem Cells
BMP2: Bone Morphogenic Protein
CAFs: Carcinoma Associated Fibroblasts
CD 95: Cluster of Differentiation 95
CDKs: Cyclin-Dependent Kinases
cDNA: complementary Deoxyribonucleic Acid
CFU-Fs: Colony Forming Unit Fibroblasts
Ct: Cycle threshold
CTL: Cytotoxic T-Lymphocyte
dATP: deoxyadenosine Triphosphate
DCs: Dendritic Cells
dCTP: deoxycytidine Triphosphate
DDR:DNA Damage Response
DEPC: Diethyl pyrocarbonate
dGTP:deoxyguanosine Triphosphate
DMEM: Dulbecco’s Modified Eagle’s Medium
DNA: Deoxyribonucleic Acid
DNAase: Deoxyribonuclase
dNTPs: Deoxynucleotide Triphosphate
DPSCs: Dental Pulp Stem Cells
DR: Death Receptor
dTTP: deoxythymidine Triphosphate
E1: ubiquitin-activating enzyme
E2: ubiquitin-conjugating enzyme or UBC
E3: ubiquitin protein ligase
E4: ubiquitin chain-assembly factor
ECM: Extra-Cellular Matrix
EDTA: Ethylene Diamine Tetra Acetate
ELISA: Enzyme-Linked Immunosorbent Assay
ER: Endoplasmic Reticulum
ESCs: Embryonic Stem Cells
FasL: Fas Ligand
FBS: Fetal Bovine Serum
GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase
HeLa Cells: Cell line derived from cervical cancer cells taken “Henrietta Lacks”
HEp2: Human Epithelial type 2 cells
HGF: Hepatocyte Growth Factor
HKGs: Housekeeping Genes
HLA: Human Leucocyte Antigen
HLA-DR: Human Leukocyte Antigen - antigen D Related
HNSCC: Head and Neck Squamous Cell Carcinoma
HPRI: Human Placental Ribonuclease Inhibitor
HSCs: Hematopoietic Stem Cells
IAPs: Inhibitor of Apoptosis of Proteins
ICAM-1: Intra-Cellular Adhesion Molecule-1
IFN-γ/IFN-α/IFN-β: Interferon gamm/alpha/beta
IGF-1: Insulin-like Growth Factor-1
IL-6: Interleukin 6
Ink4: INhibitors of CDK4
iPS cells: induced Pluripotential Stem cells
IκB α: Inhibitor of kappa B alpha
JNK: c-Jun N-terminal Kinase
lacZ: bacterial beta-galactosidase
LIF: Leukemia Inhibitory Factor
MAPK: Mitogen Activated Protein Kinase
MCF-7: Michigan Cancer Foundation-7 (breast cancer cell line)
M-CSF: Macrophage Colony-Stimulating Factor
MHC:Major Histocompatibility Complex
ML-IAP: Melanoma Inhibitor of Apoptosis
MMLV: Moloney Murine Leukemia Virus
mRNA: Messenger Ribonucleic Acid
MSCs: Mesenchymal Stem Cells
MTT: Mosmann’s Tetrazole Test/ Methyl Thiazol Tetrazlium
NeuN: neuron specific protein
NF-κB: Nuclear Factor kappa B
NK: Natural Killer
NSE: Neuron Specific Enolase
OSCC: Oral Squamous Cell Carcinoma
PARP: Poly ADP-Ribose
PBS: Phosphate Buffer Saline
PGE2: Prostaglandin E2
PGF: Placental Growth Factor
pH: potential of Hydrogen
PI3K/AKT: Phosphoinositide 3-Kinase pathway/ AK murine Thymoma
PLA: Processed Lipoaspirate
PS: Phosphatidylserine
Rb protein: Retinoblastoma protein
RING: Really Interesting New Gene
Rpm: Rounds per minute
RQ: Relative Quantification
RT-PCR: Reverse Transcriptase Polymerase Chain Reaction
SCC: Squamous cell Carcinoma
SCF: Stem Cell Factor
SDF-1: Stromal Cell Derived Factor-1
SHEDS: Stem Cells from Human Exfoliated Deciduous
siRNA: small interfering Ribonucleic Acid
SMAC/Diablo: Second Mitochondria-Derived Activator of Caspase/Direct IAP binding protein with low pH
SPSS: Statistical Package for the Social Science
SVF: Stromal Vascular Fraction
TAFs: Tumor Associated Fibroblasts
TFG-β: Transforming Growth Factor beta
TNFR1: TNF Receptor type
TNF-α: Tumor Necrosis Factor- alpha
TRAF2: TNF Receptor Associated Factor 2
UBC: Ubiquitin-Conjugating enzyme
VEGF: Vascular Endothelial Growth Factor
VSEL: Very Small Embryonic- Like
تصفح الوعاء  

Thesis 2016
Elkersawy,Rabab Rabie Abdelfattah
618 أمراض النساء والولادة والموضوعات ذات الصلة  
Beta thalassemia - Thalassemia major - Thalassemia intermedia - Thalasemic osteoprosis - Bone remodeling - Bone marker - Procollagen I N-terminal propeptide - PINP - DEXA scan of B- thalassemia
تصفح الوعاء  

Thesis 2014
Dimitry,Mark Onsy
616 الأمراض  
N-Terminal Pro-Brain Natriuretic Peptide
تصفح الوعاء  

Thesis 2012
Mohamed,Belal Mohamed.
610 الطب والعلوم الطبية   610 الطب والعلوم الطبية  
N-TERMINAL - NATRIURETIC PEPTID - PERINATAL HYPOXIA
Ain Shams university.
تصفح الوعاء  

Thesis 2008
Ibrahim,Amgad Aly El-Desokey
618 أمراض النساء والولادة والموضوعات ذات الصلة  
N-terminal
تصفح الوعاء  

Thesis 2013
Abdo,Ahmed Metwally
616 الأمراض  
Hematopoietic stem-cell transplantation (HSCT) offers a unique opportunity for long-term disease control to many patients with severe malignant or non-malignant - acquired or congenital disorders of the hematopoietic system - or with chemo-sensitive - radiosensitive or immuno-sensitive tumors. Stem cells from peripheral blood - bone marrow or cord blood are used as the graft product. HSCT has seen rapid expansion over recent decades. It is considered the treatment of choice in several circumstances - and it is integrated into the treatment algorithm for many disease categories from diagnosis.
Still - HSCT is associated with substantial morbidity and mortality. Patients and treating physicians face the challenge of deciding for or against a treatment with early risks of transplant-related mortality but the late benefit of long-term disease control. The dilemma increases when relatively non-toxic alternative therapies are available - even when their long-term benefit is yet unclear. However - most of complications could be predicted by proper assessment & so - could be prevented or at least decrease its severity.
Comorbidities are defined as any concurrent health condition or process that coexists with or may occur during the clinical course of a patient with a primary (index) disease or procedure that is being studied. Comorbidities can affect the moment of detection - prognosis - therapy and patient outcome in a variety of diseases.
Patients with liver dysfunction have an increased risk of developing early and late complications after hematopoietic stem-cell transplantation (HSCT). That’s why it is mandatory to evaluate liver status before transplantation in all cases. This evaluation should allow us to decide whether HSCT can be performed or whether we should adopt measures focused on preventing these complications. The evaluation of the liver in an HSCT candidate requires the collection of information by history-taking - physical examination - liver-function tests and - occasionally - imaging tests and liver biopsy. Additionally - as infection by hepatitis B or C viruses represents the most relevant cause of hepatic dysfunction after HSCT - the serological status of the patient should be carefully evaluated.
HBsAg + patients with an active hepatitis have an increased risk for VOD in the early phase after HSCT - recovery of cellular immunity 3-6 months after HSCT can result in HBV re-activation with a biochemical hepatitis that in up to 12% of cases can be fulminant.
Recommendations: If physical examination or LFTs suggest a chronic liver disease - try to perform a liver biopsy. If severe hepatic fibrosis or cirrhosis exists - HSCT using high-dose chemo-radiotherapy is contraindicated. If AST/ALT are normal; HSCT not contraindicated (no higher risk of VOD). If AST/ALT are increased; try to delay HSCT (increased risk of VOD).
In all cases test HBeAg - anti-HBe and HBV DNA:
a. All HBV DNA-positive patients should receive prophylactic antiviral therapy (lamivudine 100 mg/day orally during immunosuppression).
b. If HBV DNA-negative: monitor after HSCT and start antiviral therapy if becomes positive.
c. If pre-core mutant form (HBeAg - anti-HBe+‏ - HBV DNA‏+) there is increased risk of fulminant hepatic failure - so use prophylactic antiviral therapy.
In HBsAg- but anti-HBc+ and anti-HBs± patients; possible HBV reactivation is up to 20% of patients (reverse seroconversion). Recommendations are to test HBV DNA after HSCT and consider antiviral therapy if it becomes positive.
In HCV DNA + patients: some but not all authors have found association with HCV infection and VOD risk. Recovery of cellular immunity 3-6 months after HSCT can result in an HCV reactivation with biochemical hepatitis - but fulminant cases are exceptional. Although the long-term expected incidence of cirrhosis in these patients was considered low (<5%) - a long-term follow-up has shown an incidence of 24% at 20 years.
Recommendations: If physical examination or LFT suggest chronic liver disease - try to perform a liver biopsy. If severe hepatic fibrosis or cirrhosis exists; HSCT using high-dose chemo-radiotherapy is contraindicated. If there is chronic hepatitis with neither severe fibrosis nor cirrhosis; HSCT is not contraindicated. If AST/ALT are normal; HSCT is not contraindicated. If AST/ALT are increased; try to delay HSCT (increased risk of VOD) ; if it cannot be delayed ; consider treatment with ribavirin - interferon or peginterferon.
Cytomegalovirus (CMV) remains a major pathogen for solid organ transplant recipients - causing febrile syndromes - hepatitis - pneumonitis - retinitis - and colitis. Because CMV produces lifelong latent infection - differentiation of latent infection from active disease in immuno-compromised individuals presents a diagnostic challenge. All allogeneic bone marrow recipients are at risk for CMV pneumonia after HCT; however - the risk is highest in sero-negative recipients who receive marrow from a seropositive donor. Other risk factors include viral shedding from other sites - viremia - chronic steroid use - and GVHD. The use of sero-negative blood products and leukocyte–depleted platelets greatly reduces - but does not eliminate the risk of developing CMV pneumonitis in sero-negative recipients.
Although HSCT-associated cardiac toxicity has become less common in recent years using modern regimens - a wide range of incidences of mortality and morbidity are still being reported in small and large series of patients. As a general rule - an ejection fraction of ≥35-40% has been accepted as reasonable evidence of adequate cardiac reserve for HSCT. Ejection fraction does correlate weakly with survival and functional status; however - haemodynamic status - functional status - N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin are all independent predictors of prognosis and merit consideration when deciding who is fit for HSCT. Tissue perfusion - especially of the brain - correlates better with symptomatic status and biochemical markers of heart failure than ejection fraction.
Baseline pulmonary function tests should be performed prior to allogeneic HCT. A decreased diffusing capacity or an increased alveolar–arterial oxygen gradient - are independent risk factors for interstitial pneumonitis and for overall mortality after transplantation. Nevertheless - these findings alone should not preclude HCT - since they are less predictive of outcome than other factors - such as relapse status and the degree of donor–recipient HLA matching. Furthermore - there is no level of pulmonary function abnormality that is uniformly predictive of death - and many patients referred for allogeneic HCT have no other viable treatment options.
Age is a poor predictor of BMT outcome in both allogeneic and autologous transplantation. Pediatric patients may have a better outcome when compared to adults. Older adults may have a somewhat higher risk of transplant-related mortality than do younger adults. However - no study has definitively established a chronologic age at which the risk of the transplant is prohibitive. Age by itself should not be used as criteria to include or exclude a patient from Transplant.
تصفح الوعاء  

Thesis Pediatrics
Mansour، Walaa Atif Abdel-Mohymen
Ain Shams uni. Medicine. Pediatrics

Thesis 2008 .
Youssef,Walaa Youssef
Ain Shams University. Faculty of Medicine. Department of Pediatrics.
تصفح الوعاء  


من 2
 







Powered by Future Library Software.All rights reserved © CITC - Mansoura University. Sponsored by Mansoura University Privacy Policy